Eutectic crystal of lenvatinib and benzoic acid, and preparation method thereof

A technology of lenvatinib and benzoic acid, applied in the field of medicinal chemistry, can solve the problems of limited clinical application, poor water solubility of lenvatinib mesylate, high cost, etc.

Active Publication Date: 2020-10-20
TIANJIN UNIVERSITY OF TECHNOLOGY
View PDF7 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Most of the lenvatinib currently used in China is imported, which is expensive and unaffordable for ordinary patients, which limits clinical application
In addition,

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Eutectic crystal of lenvatinib and benzoic acid, and preparation method thereof
  • Eutectic crystal of lenvatinib and benzoic acid, and preparation method thereof
  • Eutectic crystal of lenvatinib and benzoic acid, and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0039] Example 1

[0040] Weigh 600 mg of lenvatinib and 172 mg of benzoic acid, add 4 mL of acetonitrile and 4 mL of water to obtain a suspension, place the suspension at room temperature and stir for 1 h, filter, and dry the white solid obtained at 50°C to obtain lenvatinib and The yield of the solid sample of the benzoic acid co-crystal was 88.2%.

Example Embodiment

[0041] Example 2

[0042] Weigh 60 mg of lenvatinib and 17.2 mg of benzoic acid, and add 1 mL of anisole to obtain a suspension. The suspension is stirred at room temperature for 12 hours, filtered, and the white solid obtained is dried at 50°C to obtain levatinib Solid sample co-crystal with benzoic acid.

Example Embodiment

[0043] Example 3

[0044] Weigh 60 mg of lenvatinib and 17.2 mg of benzoic acid, add 10 μL of isopropanol, and grind for 30 minutes at a frequency of 20 Hz. The white solid obtained is dried at 40° C. to obtain a solid sample of co-crystal of lenvatinib and benzoic acid.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a lenvatinib and benzoic acid eutectic crystal and a preparation method thereof, wherein in the eutectic crystal, the molar ratio of lenvatinib to benzoic acid is 1:1, and theeutectic X-ray powder diffraction pattern has characteristic peaks when the 2theta values are 6.4+/-0.2 degrees, 7.4+/-0.2 degrees, 12.5+/-0.2 degrees, 14.7+/-0.2 degrees, 16.7+/-0.2 degrees, 17.7+/-0.2 degrees and 23.8+/-0.2 degrees. According to the invention, the eutectic preparation method is simple in process, easy to control the crystallization process, good in reproducibility and suitable for industrial production; and compared with lenvatinib mesylate, the eutectic crystal of the invention has low hygroscopicity, high dissolution rate and high apparent solubility, and provides a material basis for improving the stability and oral absorption efficiency of lenvatinib and reducing the process threshold and cost of a preparation.

Description

technical field [0001] The invention relates to the technical field of medicinal chemistry, in particular to a co-crystal of lenvatinib and benzoic acid and a preparation method thereof. Background technique [0002] Pharmaceutical active ingredients usually exist in crystalline forms, such as polymorphs, hydrates, solvates, salts, and co-crystals. For the same pharmaceutical active ingredient, different crystalline forms have different physical and chemical properties. Therefore, obtaining a suitable crystalline form of a drug is of great importance in the pharmaceutical industry. The drug exists in the form of co-crystal, which can improve the stability, solubility and processability of the active ingredient of the drug, which has significant advantages. Therefore, pharmaceutical co-crystals are an effective means to improve the physicochemical properties of pharmaceutical active ingredients. [0003] The chemical name of Lenvatinib is 4-[3-chloro-4-(cyclopropylaminocar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D215/48C07C63/06A61P35/00A61P9/00C07C51/43
CPCA61P9/00A61P35/00C07B2200/13C07C63/06C07D215/48
Inventor 陈嘉媚吕文婷
Owner TIANJIN UNIVERSITY OF TECHNOLOGY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap